Background: A multi-center study in Los Angeles (USC), Kansas City (KUMC) and Dallas (UT-SWMC) quantified via predictive modeling the dynamics of cerebral perfusion regulation (CO2 vasoreactivity and cerebral autoregulation) in MCI/AD patients and cognitively normal controls under resting conditions. The goal was to develop model-based physio-markers for accurate diagnosis of MCI and pre-clinical AD, motivated by our previous findings of significant impairment of cerebral perfusion regulation in MCI and mild AD patients.
Method: Continuous spontaneous changes in arterial blood pressure, end-tidal CO2, cerebral blood flow velocity in middle cerebral arteries and cortical tissue oxygenation at lateral prefrontal cortex were recorded over two 6-8 min sessions, separated by session of slow-paced breathing (6 breaths/minute), in 53 MCI (28 APOE4 non-carriers and 25 APOE4 carriers), 33 mild AD patients (13 APOE4 non-carriers and 20 APOE4 carriers) and 74 age/sex-matched cognitively normal controls (50 APOE4 non-carriers and 24 APOE4 carriers). Using our novel modeling methodology, we obtained predictive dynamic models of cerebral perfusion regulation (dynamic CO2 vasoreactivity and cerebral autoregulation) that were used to compute a composite diagnostic index as physio-marker of cerebral perfusion regulation dynamics under resting conditions for each participant. ROC curves were computed for differentiating MCI/AD patients from cognitively normal controls, and MCI from mild AD patients (separately for APOE4 carriers and non-carriers).
Result: The ROC curves for differentiating MCI/AD patients from controls are shown in Figure 1, for APOE4 carriers and non-carriers separately, and had Area Under the Curve (AUC) of 0.95 and 0.92, respectively. The ROC curves for differentiating MCI from mild AD patients are shown in Figure 2, for APOE4 carriers and non-carriers separately, and had AUC of 0.96 and 0.92, respectively. The p-values of mean-difference t-tests for all four cases were less than 10 (highly significant).
Conclusion: Quantitative analysis of cerebral perfusion regulation (dynamic CO2 vasoreactivity and cerebral autoregulation), using predictive dynamic modeling of cerebral hemodynamics under resting spontaneous conditions, yielded a Composite Diagnostic Index that differentiated MCI or AD patients from controls, and MCI from AD patients (p < 10 for mean-difference t-test). The respective ROC curves had AUC in the range of 0.92-0.96 (see Figures 1 & 2).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.091661 | DOI Listing |
J Neurosci
January 2025
German Center for Neurodegenerative Diseases (DZNE), Magdeburg 39120, Germany
The precuneus is a site of early amyloid-beta (Aβ) accumulation. Previous cross-sectional studies reported increased precuneus fMRI activity in older adults with mild cognitive deficits or elevated Aβ. However, longitudinal studies in early Alzheimer's disease (AD) are lacking and the relationship to the Apolipoprotein-E () genotype is unclear.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA.
Background: APOE genotype is the most important genetic risk factor for Alzheimer's disease (AD), but whether it affects the proteins associated with AD risk is unclear. Circulating proteins may reveal biology underlying pathologic processes.
Methods: We evaluated log2 standardized levels of 4979 proteins quantified using modified aptamer technology [SomaScan] in plasma from 2725 participants in the Cardiovascular Health Study who were free of dementia and stroke.
Background: Previous studies have shown that carriage of the VEGF 1154A (rs1570360) and the VEGF 2578C (rs699947) alleles may confer a protective effect on the development of Alzheimer's disease (AD). However, it is unknown if these associations are APOE-dependent and whether they can be observed in asymptomatic individuals with varying levels of amyloid pathology. The aim of this study is to determine whether interactions between the APOE ε4 allele, VEGF 1154A, and VEGF 2578C are associated with amyloid load in cognitively unimpaired (CU) older adults.
View Article and Find Full Text PDFBackground: Apolipoprotein ε4 allele (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (AD) with females having higher risk than males. Compared with non-carriers, cognitively normal, middle-aged APOE4 carriers have lower cerebral blood flow (CBF) decades before clinical symptoms appear. Early intervention to protect CBF would be critical for APOE4 carriers to mitigate AD progression.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: Recent advances in Alzheimer's disease (AD) temporal biomarker modeling have revealed considerable heterogeneity in age at amyloid onset, and recently we and others identified sex and APOE differences in tau onset age and subsequent dementia development. Here we assessed whether amyloid burden, APOE-ε4 dose, and sex interact to predict estimated T+ onset age (ETOA).
Methods: Alzheimer's Disease Neuroimaging Initiative participants (N=911, Table 1) underwent serial PET imaging to quantify global cortical amyloid ([18F]Florbetapir SUVR, [18F]Florbetaben SUVR) and meta-temporal tau ([18F]Flortaucipir SUVR) burden.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!